Collaboration to Advance Molecular Imaging Technology
|
By HospiMedica staff writers Posted on 20 Oct 2003 |
A collaboration to develop a cost-effective, readily accessible molecular imaging technology that can help more clinics and hospitals diagnose cancer has been announced by Philips Medical Systems (Best, The Netherlands) and CellPoint, L.L.C. (Englewood, CO, USA).
The collaboration will combine Cellpoint's novel diagnostic imaging agent and the nuclear medicine camera of Philips to make functional imaging readily available. The agreement will utilize CellPoint's ethylenedicysteine drug conjugate technology (EC technology), a delivery system that links tissue-specific ligands (hormones, proteins, peptides) or pharmaceutical compounds to radioisotopes for cancer diagnosis and treatment. Using clinical trial data, Philips will further develop and refine imaging techniques for SKYlight, its gantry-free nuclear camera, to determine requirements for the highest possible image quality and quantitative information about patients' disease.
The companies will collaborate on CellPoint's first imaging agent, Tc-99m-EC-deoxyglucose. EC technology allows the deoxyglucose to be labeled with the radioisotope technetium-99m (Tc-99m). The agent will target tumors, while single positron emission computed tomography (SPECT) cameras will image them, including Philips' nuclear medicine cameras. Tumors absorb more glucose than surrounding tissue, so when a cancer patient is injected with this chemically linked agent, active tumors will absorb both the glucose and the radioisotope.
"Philips has outstanding SPECT technology, and we're thrilled to strategically align ourselves with them to help advance molecular imaging agents, enabling more facilities to conduct cancer screening,” said Greg Colip, CEO of CellPoint. The company obtained the worldwide license to EC technology from the University of Texas M.D. Anderson Cancer Center (Houston, USA).
Related Links:
CellPoint
Philips Medical
The collaboration will combine Cellpoint's novel diagnostic imaging agent and the nuclear medicine camera of Philips to make functional imaging readily available. The agreement will utilize CellPoint's ethylenedicysteine drug conjugate technology (EC technology), a delivery system that links tissue-specific ligands (hormones, proteins, peptides) or pharmaceutical compounds to radioisotopes for cancer diagnosis and treatment. Using clinical trial data, Philips will further develop and refine imaging techniques for SKYlight, its gantry-free nuclear camera, to determine requirements for the highest possible image quality and quantitative information about patients' disease.
The companies will collaborate on CellPoint's first imaging agent, Tc-99m-EC-deoxyglucose. EC technology allows the deoxyglucose to be labeled with the radioisotope technetium-99m (Tc-99m). The agent will target tumors, while single positron emission computed tomography (SPECT) cameras will image them, including Philips' nuclear medicine cameras. Tumors absorb more glucose than surrounding tissue, so when a cancer patient is injected with this chemically linked agent, active tumors will absorb both the glucose and the radioisotope.
"Philips has outstanding SPECT technology, and we're thrilled to strategically align ourselves with them to help advance molecular imaging agents, enabling more facilities to conduct cancer screening,” said Greg Colip, CEO of CellPoint. The company obtained the worldwide license to EC technology from the University of Texas M.D. Anderson Cancer Center (Houston, USA).
Related Links:
CellPoint
Philips Medical
Latest Business News
- AI Care Platform Adds Quantitative MRI Analysis for Multiple Sclerosis
- Danaher Completes Acquisition of Masimo to Expand Patient Monitoring Capabilities
- Endologix Adds FDA-Cleared Peripheral Thrombectomy System
- Artivion Adds FDA-Approved NEXUS System to Aortic Arch Portfolio
- Olympus Partnership Aims to Expand Access to Robot-Assisted Endoscopic Therapy
- Johnson & Johnson Launches AI-Driven Cardiac Mapping System
- Proximie Advances AI-Driven Intelligent Operating Rooms with NVIDIA Collaboration
- GE HealthCare, DeepHealth Expand AI Breast Imaging Collaboration
- Sinocare Presents AI-Driven Integrated Digital Health Solutions at CMEF
- GE HealthCare and Medtronic Expand Alliance with Intraoperative Imaging Integration
- New Partnership Advances Physical AI into Perioperative Workflows
- External Liver Assist System Receives FDA RMAT Designation
- New Partnership Expands Access to Predictive Tool for Patient Monitoring
- GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
- Medtronic and GE HealthCare Broaden Alliance Across Monitoring and Care Solutions
- Quantum Surgical Acquires NeuWave from Johnson & Johnson
Channels
Artificial Intelligence
view channel
AI Tool Predicts Chronic Kidney Disease Risk in Diabetes
Chronic kidney disease is a common and serious complication of type 2 diabetes and often progresses without obvious early symptoms, increasing morbidity and straining health systems. Many risk models were... Read more
AI Trends Report Guides Responsible, Effective Healthcare Deployment
Hospitals are under growing pressure to adopt artificial intelligence tools that improve safety, efficiency, and continuity of care without compromising quality. At the same time, clinicians need clearer... Read moreCritical Care
view channel
Home Exercise Program Advances Recovery After Aortic Dissection
Aortic dissection is a life-threatening tear in the aortic wall that can compromise blood flow to vital organs. Survivors are often advised to restrict physical activity because of concerns about blood... Read more
Noninvasive Silk Sensor Could Transform Care for Premature Infants
Monitoring premature infants often relies on multiple wired sensors and repeated blood draws to track glucose and electrolytes, which can irritate fragile skin and disrupt care. Trend information between... Read moreSurgical Techniques
view channel
AI-Designed Microneedle Patch Accelerates Diabetic Wound Healing
Chronic diabetic wounds are slow to heal and prone to infection, often leading to repeated procedures and prolonged care. Standard closure methods bring wound edges together but do not adapt to changing... Read more
Focused Ultrasound System Gains CE Mark for Liver Tumor Treatment
Liver tumors remain a major global health challenge, and many patients are not candidates for resection or conventional thermal ablation. Tumor location, underlying liver disease, and other clinical factors... Read morePatient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read moreHealth IT
view channel
Digital Heart Model Supports Targeted Ablation in Atrial Fibrillation
Atrial fibrillation is an erratic, quivering heartbeat and a leading cause of stroke. Catheter ablation is widely used to interrupt arrhythmogenic tissue, yet many patients—especially with persistent ... Read moreAI Framework Helps Clinicians Create Trustworthy Risk Prediction Tools
Artificial intelligence (AI) is increasingly used to estimate risks for conditions such as sepsis, heart disease, and cancer, yet many models remain difficult for clinicians to interpret or trust.... Read morePoint of Care
view channel
New Brain Ultrasound Platform Enables Bedside Postoperative Imaging
Transporting postoperative patients for CT or MRI can create operational burdens, delays, and disruptions in care. Bedside visualization may help reduce transport demands, lower radiation exposure, and... Read more







